Shanghai Bio-heart Biological Technology (HKG:2185) subsidiary Zhejiang Bioheart Medical Equipment will receive a 155.6 million yuan capital injection from Jiaxing Guojian Baixin Equity Investment Partnership Enterprise in exchange for a 45.3208% stake in Zhejiang Bioheart.
Upon completion of the capital increase, Shanghai Bio-heart's stake in Zhejiang Bioheart will be reduced to 54.6792%, with Jiaxing Guojian Baixin Equity Investment Partnership Enterprise holding the remainder.
Price (HKD): $1.64, Change: $-0.050, Percent Change: -2.96%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。